The cost-effectiveness of a pharmacogenetic test: A trial-based evaluation of TPMT genotyping for azathioprine

Value in Health

Volumn 17, Issue 1, 2014, Pages 22-33

  Thompson, Alexander J ^a   Newman, William G ^b   Elliott, Rachel A ^c   Roberts, Stephen A ^a   Tricker, Karen ^b   Payne, Katherine ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

cost effectiveness; pharmacogenetics; prospective; RCT; TPMT

Indexed keywords

AZATHIOPRINE; THIOPURINE METHYLTRANSFERASE;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL PATHWAY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FEMALE; FOLLOW UP; GENOTYPE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PHARMACOGENETICS; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; STANDARD;

COST-EFFECTIVENESS; PHARMACOGENETICS; PROSPECTIVE; RCT; TPMT;

AUTOIMMUNE DISEASES; AZATHIOPRINE; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; GENOTYPE; GREAT BRITAIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MODELS, ECONOMIC; PHARMACOGENETICS; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84892610103     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.10.007     Document Type: Article

References (49)

1. O.N. Ikediobi, J. Shin, and R.L. Nussbaum et al. Addressing the challenges of the clinical application of pharmacogenetic testing Clin Pharmacol Ther 86 2009 28 31
2. D. Gurwitz, and A.G. Motulsky Drug reactions, enzymes, and biochemical genetics: 50 years later Pharmacogenomics 8 2007 1479 1484
3. K.A. Phillips, and S.L. Van Bebber A systematic review of cost-effectiveness analyses of pharmacogenomic interventions Pharmacogenomics 5 2004 1139 1149
4. S. Vegter, C. Boersma, and M. Rozenbaum et al. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines Pharmacoeconomics 26 2008 569 587
5. W.B. Wong, J.J. Carlson, and R. Thariani et al. Cost effectiveness of pharmacogenomics: a critical and systematic review Pharmacoeconomics 28 2010 1001 1013
6. K. Payne, and F.H. Shabaruddin Cost-effectiveness analysis in pharmacogenomics Pharmacogenomics 11 2010 643 646
7. C.K. Rayner, A.L. Hart, and C.M. Hayward et al. Azathioprine dose escalation in inflammatory bowel disease Aliment Pharmacol Ther 20 2004 65 71
8. L. Lennard TPMT in the treatment of Crohn's disease with azathioprine Gut 51 2002 143 146
9. H.L. McLeod, S. Coulthard, and A.E. Thomas et al. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia Br J Haematol 105 1999 696 700
10. W.G. Newman, K. Payne, and K. Tricker et al. A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study Pharmacogenomics 12 2011 815 826
11. K. Chakravarty, H. McDonald, and T. Pullar et al. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists Rheumatology (Oxford) 47 2008 924 925
12. C. Mowat, A. Cole, and A. Windsor et al. Guidelines for the management of inflammatory bowel disease in adults Gut 60 2011 571 607
13. L.T. Ford, J.D. Berg, and Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment: a pharmacogenomic test whose time has come J Clin Pathol 63 2010 288 295
14. Department of Clinical Biochemistry. City Hospital, Birmingham, UK. Thiopurine S-methyl transferase (TPMT) service. Available from: http://www.cityassays.org.uk/tpmt.html [Accessed November 13, 2013]
15. K. Payne, E.A. Fargher, and S.A. Roberts et al. Valuing pharmacogenetic testing services: a comparison of patients' and health care professionals' preferences Value Health 14 2011 121 134
16. S.J. Meggitt, A.V. Anstey, and M.F.M. Mustapa et al. British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011 Br J Dermatol 165 2011 711 734
17. E.A. Fargher, K. Tricker, and W. Newman et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription J Clin Pharm Ther 32 2007 187 195
18. K. Payne, W.G. Newman, and D. Gurwitz et al. TPMT testing in azathioprine: a 'cost-effective use of healthcare resources'? Personalized Med 6 2008 103 113
19. J. Winter, A. Walker, and D. Shapiro et al. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease Aliment Pharmacol Ther 20 2004 593 599
20. V.L. Priest, E.J. Begg, and S.J. Gardiner et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease Pharmacoeconomics 24 2006 767 781
21. M.J. Sculpher, K. Claxton, and M. Drummond et al. Whither trial-based economic evaluation for health care decision making? Health Econ 15 2006 677 687
22. National Institute for Health and Care Excellence Diagnostics Assessment Programme Manual 2011 National Institute for Health and Care Excellence London, UK
23. P. Dolan, C. Gudex, and P. Kind et al. A social tariff for EuroQol: results from a UK general population survey Discussion Paper 1995
24. A. Manca, N. Hawkins, and M.J. Sculpher Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility Health Econ 14 2005 487 496
25. Department of Health. National Schedule of Reference Costs Year: '2009-10'. London, UK: Department of Health; 2012.
26. Curtis L. Unit costs of health and social care. November 2010. Available from: www.pssru.ac.uk. [Accessed November 13, 2013].
27. British Medical Association and the Royal Pharmaceutical Society of Great Britain British National Formulary 2010 BMJ Publishing Group London, UK
28. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment 2010 2009 Norwegian Institute of Public Health Oslo, Norway
29. A. Burton, L.J. Billingham, and S. Bryan Cost-effectiveness in clinical trials: using multiple imputation to deal with incomplete cost data Clin Trials 4 2007 154 161
30. I.R. White, P. Royston, and A.M. Wood Multiple imputation using chained equations: issues and guidance for practice Stat Med 30 2011 377 399
31. M. Hernandez Alava, A.J. Wailoo, and R. Ara Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values Value Health 15 2012 550 561
32. D.B. Rubin, and N. Schenker Multiple imputation in health-care databases: an overview and some applications Stat Med 10 1991 585 598
33. J.S. Hoch, A.H. Briggs, and A.R. Willan Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis Health Econ 11 2002 415 430
34. W.G. Manning, and J. Mullahy Estimating log models: to transform or not to transform? J Health Econ 20 2001 461 494
35. H.A. Glick, J.A. Doshi, and S.S. Sonnad et al. Economic Evaluation in Clinical Trials A. Gray, A. Briggs, Handbooks in Health Economic Evaluation 2007 Oxford University Press Oxford 108 111
36. A. Basu Extended generalized linear models: simultaneous estimation of flexible link and variance functions Stata J 5 2005 501 516
37. B.J. O'Brien, and A.H. Briggs Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods Stat Methods Med Res 11 2002 455 468
38. C. McCabe, K. Claxton, and A.J. Culyer The NICE cost-effectiveness threshold: what it is and what that means Pharmacoeconomics 26 2008 733 744
39. National Institute for Health and Care Excellence Guide to the Methods of Technology Appraisal 2013 National Institute for Health and Care Excellence London, UK
40. R.M. Nixon, D. Wonderling, and R.D. Grieve Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared Health Econ 19 2010 316 333
41. UK Genetic Testing Network. National Tariff Proposals for Molecular Genetic Testing. 2006. Available from: http://www.ukgtn.nhs.uk/gtn/ digitalAssets/0/611-NationalTariffReport.pdf. [Accessed March 30, 2013].
42. S. Ramsey, R. Willke, and A. Briggs et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report Value Health 8 2005 521 533
43. A.H. Briggs, and A.M. Gray Power and sample size calculations for stochastic cost-effectiveness analysis Med Decis Making 18 2 Suppl. 1998 S81 S92
44. K. Claxton The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies J Health Econ 18 1999 341 364
45. Kennedy I. Appraising the value of innovation and other benefits: a short study for NICE. July 2009. Available from: http://www.nice.org.uk/media/98f/5c/ kennedystudyfinalreport.pdf. [Accessed November 13, 2013].
46. A. Wailoo, S. Davis, and J. Tosh The Incorporation of Health Benefits in Cost Utility Analysis Using the EQ-5D 2010 Decision Support Unit London: NICE
47. M.J. Harrison, L.M. Davies, and N.J. Bansback et al. The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review J Rheumatol 35 2008 592 602
48. S.J. Gardiner, R.B. Gearry, and E.J. Begg et al. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold Clin Gastroenterol Hepatol 6 2008 654 660 (quiz 604)
49. A. Qasim, J. Seery, and M. Buckley et al. TPMT in the treatment of inflammatory bowel disease with azathioprine Gut 52 2003 767 (author reply 767-7)